# Amycretin > Novo Nordisk’s single-molecule GLP-1 + amylin receptor agonist (INN zenagamtide) — CagriSema’s two pathways in one peptide, in Phase 3 as a weekly injection with an oral form in development. - Also known as: Zenagamtide - Class: Metabolic - FDA approved: No - Canonical page: https://americanpeptide.com/catalog/amycretin ## Overview Amycretin, now carrying the international name zenagamtide, is an investigational unimolecular agonist of both the GLP-1 and amylin receptors. Where CagriSema reaches those two satiety pathways by co-formulating two peptides, amycretin does it with one — and is being developed in both subcutaneous and oral forms. An early subcutaneous study (Lancet 2025) reported 24.3% mean weight reduction at 36 weeks on the highest dose. Novo Nordisk began the Phase 3 AMAZE obesity program in early 2026. It is not approved anywhere. The GLP-1 and amylin pathways suppress appetite through different receptors in different parts of the brain, and engaging both is additive — the premise of CagriSema. Amycretin is Novo Nordisk’s attempt to put both activities into a single molecule, which simplifies manufacturing and dosing ratios and, critically, makes an oral version feasible in a way a two-peptide combination is not. The early data drew attention because of how fast the weight came off. A Phase 1b/2a trial of the once-weekly subcutaneous form (Lancet 2025) reported estimated mean weight reduction of 24.3% at 36 weeks on the top dose, with no plateau at the end of treatment. A Phase 1 trial of the once-daily oral form reported about 13% at just 12 weeks. Both were small, short studies in which participants were titrated quickly, and gastrointestinal adverse events were common — the figures are signals, not Phase 3 estimates. Phase 3 began in 2026: the AMAZE program opened its first obesity trial in February, followed by a weight-maintenance study, with the subcutaneous form leading. In type 2 diabetes, a Phase 2 trial presented at ADA 2026 reported significant HbA1c reductions with up to 14.6% weight loss. No Phase 3 efficacy data exist yet, and primary completion of the lead obesity trial is not expected for several years. ## Mechanism One peptide with agonist activity at both the GLP-1 receptor and amylin receptors — GLP-1-mediated insulin secretion and appetite suppression combined with amylin-mediated hindbrain satiety and slowed gastric emptying. ## Research areas Studied in: Obesity, Type 2 diabetes, Oral incretin therapy, Combination satiety pathways. Guides on this site: - [Weight Loss & Metabolic Health](https://americanpeptide.com/research-areas/weight-loss): Incretin and metabolic peptides studied for glycemic control and fat loss. ## Key research - Unimolecular GLP-1 + amylin agonism — one peptide engaging both satiety pathways, versus CagriSema’s two-peptide co-formulation. - Subcutaneous Phase 1b/2a (Lancet 2025) — 24.3% estimated mean weight reduction at 36 weeks on the highest weekly dose; no plateau observed. - Oral form — a once-daily tablet reported ~13% mean weight reduction at 12 weeks in Phase 1. - Type 2 diabetes — Phase 2 data (ADA 2026) reported significant HbA1c reductions with up to 14.6% weight loss. - Status — Phase 3 AMAZE program began in early 2026; investigational, no Phase 3 results yet. ## FAQs ### What is amycretin? Amycretin (INN zenagamtide) is an investigational Novo Nordisk peptide that activates both the GLP-1 and amylin receptors in a single molecule. It is in Phase 3 for obesity as a once-weekly injection, with an oral version also in development. ### Is zenagamtide the same as amycretin? Yes. Zenagamtide is the international nonproprietary name assigned to the compound previously known by its development name, amycretin. ### How is amycretin different from CagriSema? Both combine GLP-1 and amylin activity. CagriSema is two separate peptides — semaglutide and cagrilintide — in one injection. Amycretin is a single peptide with both activities, which also allows an oral formulation. ### How much weight do people lose on amycretin? An early subcutaneous trial (Lancet 2025) reported 24.3% mean weight reduction at 36 weeks on the top dose, and an oral Phase 1 trial about 13% at 12 weeks. These were small early-phase studies; Phase 3 results are not yet available. ### Is amycretin approved? No. It is investigational everywhere, with Phase 3 trials that began in 2026. Anything sold as amycretin today is outside any regulated channel. This page is a research reference, not medical advice. ## Latest research Recent trials and publications mentioning Amycretin, pulled automatically from ClinicalTrials.gov and PubMed (unfiltered search results, refreshed daily). ### Recent trials - [A Research Study of How a New Medicine Called Amycretin, Given as Tablets, Works in Japanese Men With Obesity](https://clinicaltrials.gov/study/NCT06049329) — COMPLETED · PHASE1 · NCT06049329 --- Source: AmericanPeptide.com — https://americanpeptide.com/catalog/amycretin Data license: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Attribution: AmericanPeptide.com. Research reference only — computational and educational content, not medical advice.